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Abstract
Background: Prosaposin encodes, in tandem, four small acidic activator proteins (saposins) with
specificities for glycosphingolipid (GSL) hydrolases in lysosomes. Extensive GSL storage occurs in
various central nervous system regions in mammalian prosaposin deficiencies.
Results: Our hypomorphic prosaposin deficient mouse, PS-NA, exhibited 45% WT levels of brain
saposins and showed neuropathology that included neuronal GSL storage and Purkinje cell loss.
Impairment of neuronal function was observed as early as 6 wks as demonstrated by the narrow
bridges tests. Temporal transcriptome microarray analyses of brain tissues were conducted with
mRNA from three prosaposin deficient mouse models: PS-NA, prosaposin null (PS-/-) and a V394L/
V394L glucocerebrosidase mutation combined with PS-NA (4L/PS-NA). Gene expression
alterations in cerebrum and cerebellum were detectable at birth preceding the neuronal deficits.
Differentially expressed genes encompassed a broad spectrum of cellular functions. The number of
down-regulated genes was constant, but up-regulated gene numbers increased with age. CCAAT/
enhancer-binding protein delta (CEBPD) was the only up-regulated transcription factor in these
two brain regions of all three models. Network analyses revealed that CEBPD has functional
relationships with genes in transcription, pro-inflammation, cell death, binding, myelin and
transport.
Conclusion:  These results show that: 1) Regionally specific gene expression abnormalities
precede the brain histological and neuronal function changes, 2) Temporal gene expression profiles
provide insights into the molecular mechanism during the GSL storage disease course, and 3)
CEBPD is a candidate regulator of brain disease in prosaposin deficiency to participate in
modulating disease acceleration or progression.
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Background
The physiological importance of prosaposin has been
demonstrated by the genetic deficiencies of individual
saposins or prosaposin that lead to various glycosphingol-
ipid (GSL) storage diseases [1-4]. Saposin B deficiency
leads to sulfatide accumulation and a metachromatic leu-
kodystrophy-like disease [4] that is similar to the defi-
ciency of arylsulfatase A, its cognate enzyme. Saposin C
activates acid β-glucosidase and its deficiency leads to a
Gaucher-like disease with an excess accumulation of gluc-
osylceramide in cells [2]. Saposin A deficiency in mice
results in a late onset, chronic form of globoid cell leukod-
ystrophy [5], whereas deficiency of saposin D in mice
causes a loss of Purkinje cells and urinary system defects
[6]. The critical roles for saposins in GSL metabolism are
highlighted by the extensive GSL storage in various central
nervous system (CNS) regions in the human and mouse
prosaposin deficiencies [1,3]. This deficiency leads to
gross abnormalities in CNS degradation of lactosylcera-
mide (LacCer), glucosylceramide (GC), sulfatide and
galactosylceramide with consequent pathologic accumu-
lation of these GSLs and gangliosides.
Targeted disruption of prosaposin in the mouse leads to a
complex neurodegeneration with neuronal and micro-
glial accumulation of GSLs, and demyelination [1]. The
excesses of GSLs lead to neuronal losses with regional spe-
cificity and death by ~30 days [1]. Our hypomorphic pro-
saposin model PSKO-TG (PS-NA) containing a
prosaposin transgene has 45% of saposin protein expres-
sion in brain, survives up to 220 days and has delayed
onset of neuropathological changes and Purkinje cell loss
compared to the null mouse [7]. Another mutant mouse,
4L/PS-NA, has the acid β-glucosidase V394L/V394L (4L)
point mutation combined with hypomorphic expression
of the prosaposin transgene (PS-NA) [8]. This mouse
shows accumulation of GC in visceral organs and the CNS
in excess of that in either 4L [9] or PS-NA mice. Similar to
PS-NA mice, 4L/PS-NA mice develop a neurological phe-
notype and loss of Purkinje cells. Neuronal GSL storage
and activated microglia/macrophage cells and astrocytes
in CNS are common pathologies in all three models.
Here, the temporal course of the neuronal phenotypes
was correlated with the molecular profile of disease pro-
gression in these prosaposin deficiency mouse models.
Microarray analyses revealed the common transcription
factors that underlie prosaposin pathology and their rela-
tionship to development of the neurological phenotype.
The results provide insights into the molecular mecha-
nisms and the potential for strategic interventions for this
class of diseases, as well as other acquired CNS degenera-
tive disorders that involve GSL.
Results
Description of prosaposin deficient mouse models
Three mouse models with prosaposin deficiencies are
included in this study (Table 1). Prosaposin knock out
mice (PS-/-) live about 30 days and have progressive accu-
mulation of LacCer, GC, ceramide and total ganglioside
sialic acid in the CNS [1]. Neuronal GSL storage is evident
in PS-/- newborn brains [10]. PS-/- mice show the onset of
neurological signs at ~20 days of age and the phenotype
rapidly progresses during the next 5–10 days. PS-NA mice
have ~45% of normal levels of prosaposin protein expres-
sion in the brain and lesser levels in other tissues [7]. They
survive up to 32 wks with slow progression of neurologi-
cal deficits. LacCer and GC are the predominant excess
neutral GSLs in the PS-NA brains. PS-NA mice produced
normal size litters and this model was subjected to neuro-
logical and behavioral testing. 4L/PS-NA mice are
homozygous for a gba  mutant gene encoding a V394L
GCase against the PS-NA background [8]. The phenotype
includes an average life span ~22 wks, progressive neuro-
logical deficits, and greater excesses of GC accumulation
in brain and visceral tissues than those in PS-NA mice. PS-
/- mice did not reproduce and 4L/PS-NA had reduced fer-
tility. PS-NA and PS-/- mice were in the FVB strain back-
ground. 4L/PS-NA mice were in a mix strain background
(50% FVB, 25% C57BL/6, 25% 129SvEvBrd). WT mice in
the FVB background were used as controls in this study.
Impairment of neurological function
Deterioration of neurological function was formally
assessed in the PS-NA mice. The narrow bridges test was
Table 1: Prosaposin deficient mouse models
Genotype Strain (%) Life Span Major CNS lipids 
(Accumulation level)
CNS phenotype Prosaposin level in 
CNS (% WT)
References
PS-/- FVB ~4 wks 14 – 30 day
GC (+ → +++)
LacCer (+ → +++)
Ataxia, Tonic status 
epileptics
0 [1,10]
PS-NA FVB 32 wks 4 – 22 wk
GC (- → +)
LacCer (- → +)
Ataxia, waddling gait 45 [7]
4L/PS-NA FVB (50)
C57BL/6 (25)
129SvEvBrd (25)
22 wks 4 – 20 wk
GC (+ → +++)
LacCer (- → +)
Ataxia, waddling gait 45 [8]BMC Neuroscience 2008, 9:76 http://www.biomedcentral.com/1471-2202/9/76
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performed to evaluate balance and motor performance
(Fig. 1). Different levels of task difficulty were assessed
with round- and square-shaped beams with varying cross-
sectional areas. At 6 wks, control and PS-NA mice walked
along the beam with similar latencies (Fig. 1A). However,
PS-NA mice made significantly more foot slips than con-
trols on medium and narrow beams (Fig. 1B). At 10 wks,
PS-NA mice were already significantly slower in traversing
the narrowest round and square beams, and the number
of foot slips increased on medium and small square
beams. Between 12 to 18 wks, PS-NA mice showed
increased difficulty in traversing all beams, as measured
by their increased latency and foot slips compared with
control mice (Fig. 1A and 1B). At 8 wks or younger, both
control and PS-NA mice walked on the beam with an
upright posture, but by 12 wks of age, PS-NA mice dis-
Progressive neurological deficits Figure 1
Progressive neurological deficits. (A, B) Narrow bridges. Mice were trained for three days. The latency to cross the bridge 
(A) and the number of foot slips (B) on a round wood beam (11 mm) were recorded (PS-NA, n = 10; WT, n = 10). PS-NA 
mice [open triangles] made significantly more foot slips and slower latency than WT [black squares] (*p < 0.05, **p < 0.01, ***p 
< 0.001). (C) Locomotor test at 18 wks. The mice were placed in an activity chamber for 120 min and locomotor activity was 
recorded in 5 min intervals (PS-NA, n = 5; WT, n = 5). PS-NA [open triangles] mice showed progressive failure to habituate 
compared to WT [black squares] mice.
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played ventral recumbence; their abdomen was flattened
on the surface of the beam, their hind- and fore-limbs
were wrapped around the beam, and the fore-limbs were
used to drag themselves along the beams. By 14 wks, some
mutant mice failed to maintain balance and started to fall,
but used their forelimbs to regain balance. PS-NA mice
exhibited progressive deterioration in performance on the
narrow bridges test until 22 wks.
Locomotor activity is a test of general exploration and
response to novelty. PS-NA and WT control mice took >
120 min for adaptation. PS-NA mice showed measurable
motor differences starting at 10 wks and the effect was
more pronounced by 22 wks. They demonstrated hyper-
activity with increases of beam breaks (Fig. 1C), and were
active longer than controls. No difference between center
and peripheral activity was observed. These results suggest
that the deficiency of prosaposin results in a progressive
failure to habituate in PS-NA mice, compared to WT mice
that showed habituation over the test period. The altered
motor function was significant beginning at 12 wks.
Gait was analyzed by footprint patterns while the mice
walked through a runway. Between control and PS-NA
mice, no significant differences were found before 21 wks
for stride length or fore- and hind-paw overlap. By 21 wks,
PS-NA mice exhibited significantly increased hind-paw
base width from the controls (data not shown).
Brain neuropathology in prosaposin deficient mice
By EM, no inclusions were observed at 4 wks in PS-NA or
WT mouse brains. Inclusion bodies were present in neu-
rons of PS-NA mice by 18 wks (Fig. 2). Such inclusions
were observed in brain stem, midbrain and cerebral cor-
tex, but rarely in Purkinje cells. 4L/PS-NA mice had neu-
ronal storage similar to that in PS-NA brains. However,
4L/PS-NA mice showed large amounts of storage in gran-
ular cells of the cerebellum; this is not observed in PS-NA
mice [8]. PS-/- mice show inclusions in neurons of various
regions in the brain [10].
Extensive neuronal degeneration was found in all the pro-
saposin deficient mouse brains. The specific neuronal
stain, NeuN, was decreased in the cerebral cortex at 12 and
18 wks in PS-NA mice. Losses of cerebellar Purkinje cells
were demonstrated with anti-Calbindin D28K, a Purkinje
cell marker, beginning at 12 wks (Fig. 3A). Neuronal
degeneration and decreases in Purkinje cell numbers were
also observed in 4L/PS-NA mice. PS-/- mice showed neu-
ronal degeneration in thalamus and cortex starting at ~20
days; no Purkinje cell loss was observed (Fig. 3B).
Microarray analyses of brain tissues in prosaposin 
deficient mice
To explore the genes involved in the prosaposin defi-
ciency disease progression pathway, mRNA microarray
analyses were performed in PS-NA mice using Mouse
Genome 430 2.0 Array chips (Affymetrix). Partek®
Genomics Suite was used for statistical analyses of the
microarray data. The commonalities and specificities of
gene expression were analyzed in PS-/-, PS-NA, and 4L/PS-
NA mice. PS-/- mice (total PS deficiency) quickly develop
the neurological phenotype and have a short life span [1].
4L/PS-NA mice have the same level of prosaposin expres-
sion as PS-NA mice, but the mice have a shorter lifespan,
and also have greater GC accumulation (Table 1) [7,8].
Electron microscopy showing progressive accumulation of inclusions in neurons of PS-NA brain Figure 2
Electron microscopy showing progressive accumulation of inclusions in neurons of PS-NA brain. No inclusions 
were found in neurons of 4 wk PS-NA (A), whereas inclusion bodies were in neuron of PS-NA at 18 wk (B). An enlarged view 
of inclusion bodies is shown (C). Magnifications are 8,000 X for A and B.BMC Neuroscience 2008, 9:76 http://www.biomedcentral.com/1471-2202/9/76
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The gene profiles were analyzed in two general brain
regions, cerebrum and cerebellum, that were collected at
several time points for PS-/- (0, 10, 20 and 25 days), PS-
NA (0, 4, 12 and 18 wks) and 4L/PS-NA (4, 12, and 18
wks). The probe sets for each gene in the mutant mice that
showed significant differential gene expression were com-
pared to the age-matched WT (Table 2). The significantly
differentially expressed probe sets in the mutant models
ranged from 460 to 2000 of the 45,101 total probes on the
chip. For further analyses, the probe sets were replaced by
Neuronal degeneration in brain Figure 3
Neuronal degeneration in brain. (A) Paraffin sections were stained with a neuron marker, NeuN, and a Purkinje cell 
marker, Calbindin D28K (calbindin). Progressive decreases in NeuN stained cells (upper panel) and incremental loss of 
Purkinje cells (lower panel) were shown in PS-NA mice at 12 wk and older. The NeuN changes were generalized, but regional 
variations in neuronal loss also were evident. (B) H&E stained paraffin sections of cerebellum showed the presence of Purkinje 
cells (arrows) in PS-/- (25 day) and WT (18 wk) mice and loss of Purkinje cells in PS-NA (18 wk) and 4L/PS-NA (18 wk) mice.
Table 2: Summary of differentially expressed probesets and genes in brain regions of prosaposin deficient mouse models
PS-/- PS-NA 4L/PS-NA
Cerebellum Cerebrum Cerebellum Cerebrum Cerebellum Cerebrum
Number of differentially expressed probesets 460 468 915 462 1983 635
EST and unknown genes 58 27 112 48 156 62
Differentially expressed probesets with known genes 402 441 803 414 1827 573
Differentially expressed genes 349 367 662 366 1512 493
% of differentially expressed genes on chip 1 1.1 1.9 1.1 4.4 1.5BMC Neuroscience 2008, 9:76 http://www.biomedcentral.com/1471-2202/9/76
Page 6 of 20
(page number not for citation purposes)
the genes. ESTs and genes of unknown function were
excluded. At a false positive rate (FDR) of 0.2, the total dif-
ferentially expressed genes in each model ranged from
1.0–4.4% of the total genes on the chip. The complete lists
of differentially expressed genes, grouped for their func-
tions, are in Additional file 1.
Compared to WT mice, the total number of significantly
differentially expressed genes in each model was in the
following order: 4L/PS-NA > PS-NA > PS-/- (Table 2). In
PS-NA and 4L/PS-NA mice, the number of differentially
expressed genes was greater in cerebellum than in cere-
brum. PS-/- mice had about equal numbers of differen-
tially expressed genes in both tissues and ~20% were in
common between the cerebrum and cerebellum. Tempo-
ral profiling revealed that the number of the differentially
expressed genes increased with age in all three models
(Table 3). The differentially expressed genes were sub-
grouped into those up-regulated (expression level ≥ 1.5
fold) or down-regulated (≤ 1.5 fold) for any time point for
each tissue (Table 3). The number of up-regulated genes
was nearly constant at the second time point (10 days for
PS-/- and 4 wk for PS-NA and 4L/PS-NA), and then
increased by the third time point (20 days for PS-/- and 12
wks for PS-NA and 4L/PS-NA). The number of down-reg-
ulated genes was relatively constant throughout. Even at
birth, ~100–300 genes in cerebellum or cerebrum had dif-
ferential expression in PS-NA and PS-/- mice (Table 3);
4L/PS-NA mice were not done. Although the PS-NA and
PS-/- mice did not develop neurological signs until after 6
wks and 14 days, respectively (Table 1), the alterations of
mRNA expression preceded the neuronal deficits. These
data suggest that the number of genes involved in patho-
logical progression increased with age and varied with the
genotype and lifespan, and the molecular alterations pre-
ceded the histological and neurological changes.
Ontological analyses of the differentially regulated genes
revealed involvement in a broad spectrum of cellular
functions. The functional groups with statistical signifi-
cance across the cerebrum and cerebellum in the three
animal models included neuronal conduction (myelina-
tion and synaptic vesicles), cell growth and metabolism,
proinflammatory response (inflammation, macrophage,
extracellular matrix and cell adhesion molecules), cell
death, and signal transduction (Table 4 and Additional
file 1). All three mouse models showed similar spectra of
gene expression patterns for these functional groups,
except cerebra of PS-NA and 4L/PS-NA or cerebrum of PS-
NA which did not show significant (p > 0.05) involve-
ment of synaptic or myelination genes, respectively. Sev-
eral of these categories presented consistent increases of
up-regulated genes with age, particularly those in the
groups for inflammation and adhesion, cell death, signal
transduction, transcription factors and transport (Fig. 4
and Additional file 2). The total numbers of genes in these
groups increased with age. More than twice as many genes
were up-regulated in cerebellum than cerebrum. It is likely
that additional dysregulated genes will be identified as
sub-regions of cerebrum are analyzed. 4L/PS-NA mice had
Table 3: Temporal profile of differentially expressed genes in cerebellum and cerebrum of prosaposin deficient mouse models
Genotypes Tissues Expression Number of differentially expressed genes
0 day 10 days 20 days 25 days 4 weeks 12 weeks 18 weeks
PS-/- Cerebellum up 151 97 212 213
down 58 43 83 83
subtotal 209 140 295 296
Cerebrum up 134 70 250 288
down 22 52 66 64
subtotal 156 122 316 352
PS-NA Cerebellum up 134 238 265 390
down 164 99 87 124
subtotal 298 337 352 514
Cerebrum up 54 100 212 232
down 61 59 48 22
subtotal 115 159 260 254
4L/PS-NA Cerebellum up 436 868 831
down 270 428 313
subtotal 706 1296 1144
Cerebrum up 216 347 341
down 88 98 67
subtotal 304 445 408BMC Neuroscience 2008, 9:76 http://www.biomedcentral.com/1471-2202/9/76
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twice as many up-regulated genes as the PS-NA mice in
cerebellum or cerebrum. This was primarily associated
with more rapidly progressive neurological signs in the
4L/PS-NA mice. The mixed strains in 4L/PS-NA might also
contribute to the larger numbers of differentially
expressed genes, but the complexity of the genotype (5
separate loci) and low number of offspring precluded
exact matching of the background strains.
All three models had altered expression of many cell death
associated genes (Fig. 4). The classification of down-regu-
lated genes (Additional file 2) revealed a relatively con-
stant number with age, implying their direct relationship
to prosaposin gene deficiency. In the myelination cate-
gory, PS-/- mice had more down-regulated genes than PS-
NA and 4L/PS-NA mice. Transcription, transport and sig-
nal transduction had larger number of altered genes in PS-
NA and 4L/PS-NA mice. These results reflect differential
tissue and cellular responses to prosaposin deficiency and
GSL accumulation with age.
To identify the transcription factors likely involved in dis-
ease progression, the commonalities of expression in
these three models were analyzed (Fig. 5). As might be
expected, the PS-NA gene expression patterns were similar
to those found in 4L/PS-NA mice and these two were, in
turn, more similar than either alone to those from PS-/-
mice. CEBPD was the only transcription factor up-regu-
lated in cerebra and cerebella of all three models; this was
observed by 10 days in PS-/- mice, and by 4 wks in PS-NA
and 4L/PS-NA mice. CEBPD is a member of CCAAT/
enhancer-binding protein family. The expression of
CEBPD is found in brain throughout development and
into adulthood [11]. The age-dependent expression of
CEBPD suggests its participation in the propagation and/
or initiation of disease processes in prosaposin deficient
mice. Two other transcription factors (Fig. 5), Atf3 and
Nfia, were differentially expressed in PS-NA and 4L/PS-NA
cerebella and cerebra. Atf3 (activating transcription factor
3) is a member of CREB family of basic leucine zipper
transcription factors whose expression begins after birth.
In the cerebella of PS-NA and 4L/PS-NA mice, increases of
Atf3 expression started at 4 wks and in cerebra at 12 and
18 wks. Atf3 expression was not altered in PS-/- mice dur-
ing their 4 wk lifespan. The down-regulated transcription
factor Nfia (nuclei factor Ia) is a member of CCAAT box
binding transcription factor family. Nfia is expressed early
in embryonic development to adulthood, and is involved
in development of multiple organs, including the hippoc-
ampus [12] and cerebellar granular cells [13]. The levels of
Nfia were consistently low in cerebrum and cerebellum of
PS-NA and 4L/PS-NA mice, but were not altered in PS-/-
mice. Atf3 and Nfia could be potential candidates that reg-
ulate disease progression in prosaposin deficiency at later
ages.
The down-regulated genes were analyzed by K-means
clustering for similarities in expression profiles through-
out development (Fig. 6). The myelination-associated
genes with similar expression profiles showed decreased
Table 4: Functional classification of significantly expressed genes in cerebellum and cerebrum of prosaposin deficient mouse models
PS-/- PS-NA 4L/PS-NA
Categories Cerebellum Cerebrum Cerebellum Cerebrum Cerebellum Cerebrum
No. p-value No. p-value No. p-value No. p-value No. p-value No. p-value
Inflammation & Macrophage 34 1.10E-09 23 3.75E-04 80 1.59E-14 39 4.80E-12 147 5.53E-13 78 5.01E-13
Myelination 14 3.57E-11 13 8.21E-10 8 2.07E-03 2 *2.33E-01 11 1.19E-02 6 6.75E-03
Synapse vesicle 5 3.23E-02 14 7.75E-07 14 3.87E-04 4 *1.53E-01 35 3.63E-09 6 *8.86E-02
Cell death 13 8.94E-03 11 4.21E-02 20 1.22E-02 10 4.16E-02 50 4.83E-05 19 1.62E-03
Lipid metabolism 19 1.89E-03 22 2.91E-04 28 6.04E-03 15 3.22E-02 68 1.60E-05 31 9.57E-06
ECM/adhesion 18 1.43E-02 28 1.31E-05 55 8.58E-11 23 8.93E-04 107 7.25E-15 36 2.45E-06
Cytoskeleton organization 15 4.43E-02 20 9.32E-03 20 2.06E-02 19 1.55E-02 57 3.16E-02 26 5.79E-03
Endosome/Lysosome 12 1.32E-04 15 2.90E-06 17 1.96E-04 11 7.06E-04 32 2.11E-05 20 7.99E-08
Signal transduction 50 3.50E-03 75 2.83E-09 131 7.66E-14 68 5.37E-07 288 2.24E-14 89 4.82E-08
Transcription 67 1.70E-02 65 3.92E-02 134 7.55E-04 77 2.43E-03 292 1.01E-04 90 2.09E-02
Transport 69 2.20E-04 80 2.94E-06 108 4.10E-03 69 7.34E-04 288 9.01E-11 83 4.46E-03
Cell growth/metabolism 139 4.31E-10 204 3.13E-14 301 3.28E-07 189 9.13E-10 714 1.98E-13 237 2.87E-08
Binding 142 4.54E-06 172 2.96E-12 278 9.53E-12 169 1.94E-11 641 2.45E-15 201 6.83E-08
Catalytic activity 104 2.57E-03 138 2.96E-09 220 2.70E-08 121 2.68E-05 486 1.90E-13 153 9.12E-05
Others 46 25 71 38 171 47
The functional categories with p-value ≤ 0.05 were considered significant by hypergeometric distribution analyses using R 2.6.0 [56].
No., number of genes.
*, not significant (p > 0.05).BMC Neuroscience 2008, 9:76 http://www.biomedcentral.com/1471-2202/9/76
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Temporal expression of three functional categories ascribed to genes determined from the Gene Ontology (GO) Figure 4
Temporal expression of three functional categories ascribed to genes determined from the Gene Ontology 
(GO). The number of differentially expressed genes in Inflammation/Macrophage, Cell death and Transcription categories 
increased with age and were greater in the cerebellum than in the cerebrum. Each column represents the number of differen-
tially expressed genes at that time point. Time points for PS-NA and 4L/PS-NA are 0 day (white columns), 4 wk (line columns), 
12 wk (black columns) and 18 wk (hatched columns); for PS-/- are 0 (white columns), 10 (line columns), 20 (black columns) and 
25 (hatched columns) days.
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Regional and temporal expression of transcription genes Figure 5
Regional and temporal expression of transcription genes. (Left) Venn diagrams of the differentially expressed genes in 
PS-/-, PS-NA and 4L/PS-NA cerebellum (upper) and cerebrum (lower). The numbers in various regions represent the total of 
significantly differentially expressed genes in the intersection or complements. For example, 292 genes were significantly differ-
entially expressed in 4L/PS-NA, whereas only 3 genes were shared in PS-/-, PS-NA and 4L/PS-NA cerebellum. Very few genes 
were shared in three models: Three genes (3*; CEBPD, Efemp1 and Neurod6) in cerebellum and two genes (2*; CEBPD and 
Man2B1) in cerebrum. Only CEBPD is the common gene in two tissues of three models. There are additional 49 or 16 genes 
shared by PS-NA or 4L/PS-NA in cerebellum and cerebrum (Atf3, Nfia, etc.). (Right) Expression changes of three shared tran-
scription factors. The expression of CEBPD and Atf3 was increased and Nfia was decreased. Atf3 and Nfia were not altered in 
PS-/-. Each column presents the fold change at each time point. The dotted lines represent ± 1.5 fold. Time points for PS-NA 
and 4L/PS-NA are 0 day (white columns), 4 wk (line columns), 12 wk (black columns) and 18 wk (hatch columns); for PS-/- are 
0 (white columns), 10 (line columns), 20 (black columns) and 25 (hatch columns) days.
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Down regulated gene expression profiles by K-means clustering analyses Figure 6
Down regulated gene expression profiles by K-means clustering analyses. Upper panels: Expression levels of myelin 
associated genes were lower in cerebellum and cerebrum of PS-/- mice at 20–25 days compared to WT mice. Middle and 
Lower panels: Purkinje cell genes, Calbindin (Calb1) and Pcp2, had increase of expression in WT cerebellum with age. Expres-
sion of Calb1 and Pcp2 decreased in the cerebellum of PS-NA and 4L/PS-NA mice by 12 wks. Grid2 that also expressed in 
Purkinje cells was only decreased in 4L/PS-NA cerebellum. In PS-NA and 4L/PS-NA cerebrum, Clasp2, Creg2 and Kcnn2 were 
decreased compared to WT. Expression profiles for each cluster are shown as the log scale ratio of signal intensity to the 
median signal intensity across all samples with age (days or weeks). The right side tables show the genes in the clustering.
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expression levels in cerebellum and cerebrum of PS-/-
mice by 10 days compared to WT (Fig. 6 and Additional
file 2). These genes were not significantly altered in PS-NA
and 4L/PS-NA mice. This result is consistent with findings
that hypomyelination is a major component of the phe-
notype in PS-/- mice, but not of PS-NA mice [1,7]. PS-NA
and 4L/PS-NA mice showed losses of cerebellar Purkinje
cells (Fig. 2). Down-regulation of Calb1 (Calbindin 28 k)
and Pcp2 (Purkinje cell protein 2) was detected by 12 wks
in cerebella from PS-NA and 4L/PS-NA mice (Fig. 6). Grid
2 is a delta 2 glutamate receptor that controls synaptic
plasticity in Purkinje cells [14]. Decreases of Grid 2 were
found in the cerebellum from 4L/PS-NA mice suggesting
the loss of Purkinje cells was related to synaptic arboriza-
tion. Overall, PS-NA mice had fewer down-regulated
genes than 4L/PS-NA mice (Table 3 and Additional file 2);
this was likely associated with the more rapid develop-
ment of neurological signs in 4L/PS-NA mice than in PS-
NA mice, as well as the degree of GC accumulation. In cer-
ebrum, three down-regulated genes were shared in the PS-
NA and 4L/PS-NA brains. Creg2, a cellular repressor of the
E1A-stimulated gene, is specifically expressed in hippoc-
ampus and is involved in cellular differentiation [15].
Kcnn2 (Ca2+-activated K+  channel type 2) modulates
aspects of hippocampal learning, memory, and synaptic
plasticity [16] and is expressed only in the brain. Clasp2
(cytoplasmic linker protein associating protein) binds to
microtubule ends and is involved in cytoskeletal organiza-
tion [17]. Down-regulation of Kcnn2, Creg2 and Clasp2
suggests defects in cellular differentiation and synaptic
activity in PS-NA and 4L/PS-NA mouse brains.
With the disease progression, increasing numbers of
proinflammatory associated genes (macrophage genes,
cytokines, chemokines, complemented molecules, CD
molecules, ECM and adhesion molecules, MHC) showed
increased mRNA levels in brains of all three models
(Additional file 1) and included the macrophage
expressed genes: Csf, Ccl3, CD68, C1q, Lgals3. GFAP level
increases indicated astrogliosis in the PS deficiency dis-
eases (Additional file 1 and Fig. 7). The expression levels
of proinflammatory associated genes were up-regulated
by 4 wks and before neurological impairment. Several
extracellular matrix and proteolytic enzymes (Mmp12,
Timps, procollagen integrin b2) and lysosomal proteases
(cathepsins) involved in the proinflammatory response
also had increased expression levels. The cell death genes,
Pycard and Bcl2a1a, had elevated expression in cerebella
and cerebra from all three models. Pycard and Bcl2a1a are
apoptotic protease activator and anti apoptosis mole-
cules, respectively [18]. Casp3 was up-regulated in the cer-
ebellum from PS-NA mice, but not that from PS-/- mice
(Additional file 1 and Fig. 7), suggesting tissue and age-
dependent activation patterns. In addition, some of the
genes involved postsynaptic activity (synaptotagmin and
dynamin) and proteasome subunit proteins (Psm) and
Ubiquitin associated enzymes (Usp and Uchl)) were sig-
nificantly up-regulated in the PS-NA, 4L/PS-NA and PS-/-
models (Additional file 1), implicating altered synaptic
activity and ubiquitin proteasome metabolism in prosa-
posin deficient mice secondary to GSL accumulation in
brain.
Validation of microarray data
To validate the expression changes identified in the array
analyses, selected genes were examined in more detail by
qRT-PCR. The alterations of gene expression for CEBPD,
Atf3, Creg2, Clasp2, Grid 2 and Bcl2a1a directly corre-
sponded with the specific microarray data, e.g. increases
of mRNA for CEBPD, Atf3 and Bcl2a1a, and decreases for
Greg2 mRNA were found in the adult samples (Fig. 8). By
immunofluorescence analyses, GFAP signals in 4 wk PS-
NA brain was at WT levels. In comparison, the GFAP sig-
nals in astrocytes of 12 and 18 wk PS-NA mice were
greater. In addition, GFAP-positive astrocytes in PS-NA
mice were increased in number and were ramified across
brain regions compared to control samples (Fig. 7A). Such
astrogliosis is a hallmark of many neurodegenerative dis-
eases. A few CD68 (macrophage marker) positive cells
were present in 4 wk PS-NA brain. In 12 and 18 wk PS-NA
mice, CD68 stained microglia/macrophages in all regions
of the brain, but with increased intensities. Some of these
CD68-positive cells had increased size. Caspase 3 showed
elevated expression in Purkinje cells of the cerebellum in
12 and 18 wk brains. GFAP and CD68-positive staining
were also observed (in a similar distribution) in PS-/- and
4L/PS-NA mice (data not shown). These results were con-
sistent with the microarray analyses (Fig. 7B) and demon-
strated that astrocytes and microglia were activated in
these models and involved in the proinflammatory
response in an age-dependent manner.
CEBPD associated pathway
The differentially expressed genes in the three models
were subjected to network-based analyses to explore
CEBPD gene interactions. About 152 genes were classified
into a CEBPD- associated common pathway from all dif-
ferentially expressed genes in three models. CEBPD had
direct interactions with GFAP, MBP, IGFBP5, ATF4,
HMOX1, CEBPA, CEBPB and FOS. Those genes in turn
connected with those in multiple functional groups: tran-
scription (ATF3 and NFIA), proinflammation (CCL3,
TLR2 and CSF1), cell death (CASP3 and BCL2L), binding
(CALB1 and PCP2), myelin (MBP, PLP1 and MOG) and
transport (KCCN2) (Fig. 9A). The temporal expression
pattern (Fig. 9B) in the cerebellum from each model
showed that up-regulated genes in the CEBPD network
increased and down-regulated genes were constant with
time. The pathway does not reflect cellular specificity, butBMC Neuroscience 2008, 9:76 http://www.biomedcentral.com/1471-2202/9/76
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Immunohistochemical verification of selected genes Figure 7
Immunohistochemical verification of selected genes. (A) Consistent with microarray (chip) results, GFAP (green fluo-
rescence) showed signal enhancement in astrocytes of cerebrum in 12 and 18 wk PS-NA mice. CD68 (black) microglia/macro-
phage stains showed sparse positive cells in cerebrum of WT and 4 wk PS-NA mice. CD68 signal increases were evident in 12 
and 18 wks PS-NA mice. Caspase 3 (Casp3, green fluorescence) signals stained Purkinje cells (arrows) in PS-NA 12 wk and 
older mice. DAPI (blue fluorescence) stains nuclei. (B) Microarray (chip) results of expression changes for GFAP, CD68 and 
Caspase 3. The dotted line represents 1.5 fold. Time points for PS-NA and 4L/PS-NA are 0 day (white columns), 4 wk (line col-
umns), 12 wk (black columns) and 18 wk (hatched columns); for PS-/- are 0 (white columns), 10 (line columns), 20 (black col-
umns) and 25 (hatched columns) days.
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Quantitative RT-PCR verification of selected gene expression levels Figure 8
Quantitative RT-PCR verification of selected gene expression levels. The gene expression changes were normalized 
to actin signals and presented as the fold changes for each gene relative to age-matched WT samples. For each bar graph, the 
left is the microarray (chip) results and the right is qRT-PCR results (n = 3). The changes in expression levels from both analy-
ses trended similarly. (Time points for graph are labeled as in Figure 7).
         
       
        
     
       
          
            
     
    
CEBPD
0.1
1
10
PS- NA
4 L/ PS-
N
A
P S- / -
PS- NA
4 L/ PS-
N
A
P S- / -
F
o
l
d
 
C
h
a
n
g
e
 
(
l
o
g
 
s
c
a
l
e
)    Chip                          qRT-PCR
Cerebellum
BCL2A1A
0.1
1
10
PS- N
A
4 L/ PS- N
A
PS- / -
PS- N
A
4 L/ P S- N
A
PS- / -
F
o
l
d
 
C
h
a
n
g
e
 
(
l
o
g
 
s
c
a
l
e
) Chip                          qRT-PCR
Cerebrum
CREG2
0.01
0.1
1
10
PS- NA
4 L /
PS- NA
PS- NA
4 L/
PS- NA
F
o
l
d
 
C
h
a
n
g
e
 
(
l
o
g
 
s
c
a
l
e
)
Chip                        qRT-PCR
Cerebrum
GRID2
0.01
0.1
1
10
4 L/ PS- NA
4 L/ PS- NA
F
o
l
d
 
c
h
a
n
g
e
 
(
l
o
g
 
s
c
a
l
e
) Cerebellum
Chip                   qRT-PCR
CLASP2
0.1
1
10
P S- NA
4 L/ PS- NA
PS- NA
4 L/ PS- NA
F
o
l
d
 
c
h
a
n
g
e
 
(
l
o
g
 
s
c
a
l
e
) Cerebrum
Chip                        qRT-PCR
ATF3
0.1
1
10
PS- N
A
4 L/
PS- N A
PS- N
A
4 L/
PS- NA
F
o
l
d
 
c
h
a
n
g
e
 
(
l
o
g
 
s
c
a
l
e
)
  Chip                          qRT-PCR
CerebrumBMC Neuroscience 2008, 9:76 http://www.biomedcentral.com/1471-2202/9/76
Page 14 of 20
(page number not for citation purposes)
it provides a temporal view of dynamic changes for each
functional group in the disease course.
Discussion
Deficiency of prosaposin/saposins results in incomplete
catabolism of GSLs and their age dependent accumulation
in the brain [7,8]. To understand the molecular changes at
the transcriptome level during the disease course of prosa-
posin deficiency, three mouse models were compared in
this study by microarray analysis: 1) a complete deficiency
[PS-/-], 2) a hypomorph [PS-NA], and 3) a hypomorph
together with a GCase mutation [4L/PS-NA]. In these
three chronic neurological disease models, significant
numbers of genes were up- or down-regulated at birth
prior to any behavioral, histological or significant GSL
abnormalities. The differentially expressed genes included
those involved in transcription and signal transduction
that were early molecular responses to the insult from
incomplete GSL degradation. With age, GSL (Table 1)
accumulation became detectible and the surrounding
astrocytes and microglial cells sensed the insult and pro-
moted proinflammatory responses to maintain tissues
homeostasis. The alterations of proinflammatory genes
were common in all three models, which reflect the gen-
eralized distribution of microglial cells and astrocytes in
the brain. Prolonged proinflammatory reactions also are
present in other neurodegenerative diseases [19,20]; they
can promote beneficial effects, i.e., repair, as well as detri-
The CEBPD network Figure 9
The CEBPD network. (A) The differentially expressed genes from three models were constructed into an interaction net-
work associated with CEBPD as a master regulated gene in PathwayArchitect. 152 genes with a high confidence index of direct 
and indirect interactions with CEBPD were included in the pathway. Connecting lines between gene symbols indicate interac-
tions, the purple thick solid lines indicate the direct interactions between CEBPD and 7 genes, and they are GFAP, MBP, 
IGFBP5, FOS, CEBPB, CEBPA, ATF4 and HMOX1. Each of those genes connects to multiple functional genes highlighted with 
different color. Different types of interactions are denoted by symbols on the lines. Links scheme: Green square indicates reg-
ulation; arrow, direction of regulation; blue square with black border, binding; blue square, expression; orange circle, protein 
modification; green diamond with blue border, metabolism; green circle, promoter binding; light green triangle, transport; + in 
gray circle, positive effect; and – in gray circle, negative effect. (B) Temporal profile of CEBPD network in cerebellum of three 
models. Red nodes show gene expression level increase. Green nodes show gene expression decrease. Grey nodes present no 
significant change.BMC Neuroscience 2008, 9:76 http://www.biomedcentral.com/1471-2202/9/76
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mental or destructive effects in the brain. The loss of irre-
placeable neurons in PS-NA and 4L/PS-NA mice started at
~12 wks. The negative TUNEL assays [7] indicated an
alternative cell death pathway, e.g., necrosis or autophagy,
in these mouse brains. Importantly, neurobehavioral
impairments in PS-NA and 4L/PS-NA mice preceded
detectible neuronal cell loss, suggesting that the func-
tional impairments preceded the structural deficits, and
that the accumulating (even subclinical) GSL had direct
effects on overall cell regulation. The basis for the under-
lying neurological deficits might be attributed to synaptic
dysfunction as has been found in ataxia and Alzheimer's
disease [21,22]. Alteration of synaptic and proteosome
genes in the current models implicates GSL storage in the
lysosome as affecting synaptic function and leading to
dendritic retraction and neuronal death. As a potential
link to this pathogenic mechanism, ubiquitin proteases
that are linked to synaptic activity [22,23] were altered in
these models. Differential expression of the ubiquitin pro-
tease genes was identified in PS-/-, PS-NA and 4L/PS-NA
mouse brains and accumulation of ubiquitin was found
in the brains of all three mouse models (Sun, et al.,
unpublished observation). Clarification is needed for the
interaction between ubiquitin-dependent protein turno-
ver, and the plastic and degenerative changes at synapses
in brains with GSL accumulation.
Among the differentially expressed genes, CEBPD was the
only transcription factor up-regulated in the cerebella and
cerebra of all three mouse models. This unique common-
ality was not obscured by the potential diluting effect
from the combined analyses of sub-regions of cerebrum
or genetic background variation between 4L/PS-NA (FVB/
C57BL/129) and PS-/-, PS-NA and WT (FVB). Network
analysis indicated that CEBPD directly or indirectly con-
nects to gene functional effector pathways. For example,
CEBPD modulates GFAP and expression of numerous
cytokines through FOS mediated proinflammatory path-
ways (Fig. 9). CEBPD also modulates MBP and FOS
expression. MBP interacted with myelin-associated genes
and both MBP and FOS connected into the cell death
pathways. CEBPD has been previously implicated in
peripheral immune challenge [24] and CEBPD is up-regu-
lated after traumatic brain injury in rats and in brains
from patients with Alzheimer's disease [25,26]. Lipopoly-
saccharide (LPS) and galactosylsphingosine are exoge-
nous ligands that regulate CEBPD expression in visceral
tissues and astrocytes [27-31]. In response to LPS treat-
ment, CEBPD and NF-kB are recruited to the CNS [32].
Galactosylsphingosine, a cytotoxic metabolite of galacto-
syl ceramide found in Krabbe disease, induces expression
of cytokine mediated nuclear translocation of CEBPD
[28]. The present data suggest that accumulated GSLs in
prosaposin deficient brains might be endogenous lipids
that mediate CEBPD expression. Furthermore, CEBPD
binds to cytokine promoters in macrophages and astro-
cytes [33,34]. The expression of CEBPD is mediated by
Sp1, STAT3, c-Rel and c-Jun [35,36], whereas the down-
stream genes MBP and GFAP, as well as several inflamma-
tory genes, are modulated by CEBPD in astrocytes [30,37].
CEBPD is widely expressed in the PNS and CNS. CEBPD
in combination with CREB (cyclic AMP-responsive ele-
ment-binding protein) participates in nerve growth factor
gene transcription [38]. Curiously, the CEBPD knockout
mice have no major phenotypes except enhanced contex-
tual fear, whereas, CEBPA and CEBPB knockouts exhibit
perinatal lethality or rapid deterioration within months
after birth [39-41]. Such findings suggest that CEBPD is
not essential in non-stressed physiological development,
but may be important in response to pathological insults
by playing a role in the modulation of proinflammatory
responses and neuronal homeostasis in neurodegenera-
tive diseases. CEBPD expression was up-regulated after 10
days in PS-/- mice and after 4 wks in PS-NA and 4L/PS-NA
mice. The temporal change of this expression correlated
directly with the biochemical and histological progression
of the disease. Apparently, CEBPD plays a role in the CNS
of prosaposin deficiency mice in promoting disease pro-
gression.
Atf3 has been suggested as an "adaptive response" gene by
responding to extra- and intra-cellular changes induced by
stress signals and signals for promoting cell proliferation
[42]. Atf3 is induced by LPS and is a negative regulator of
TLR 4 and Ccl4 released from macrophages [43,44]. Atf3
has been suggested as having a role in controlling gene
expression programs required for axon regeneration [45].
The increase of Atf3 might be involved in an adaptive
response to the disease in the present models. Nfia pro-
motes gliogenesis in spinal cord [46] and directs the dif-
ferentiation of cerebellar granular neurons [47].
Disruption of Nfia in mice leads to perinatal lethality,
agenesis of the corpus callosum, and abnormal formation
of midline glial structures [12,48]. Both Atf3 and Nfia
were present in the CEBPD network, suggesting potential
interactions effects between these transcription factors.
Gene expression profiles have been studied in several lys-
osomal diseases. By serial analysis of gene expression
(SAGE), many up-regulated genes are attributed to the
proinflammation pathways in the GM2 gangliosidoses,
Tay-Sachs and Sandhoff disease patients' brains [49]. In
the severe neuronopathic Gaucher disease type 2, with
increased GC, the genes in brain associated with micro-
glial cells and astrocytes are slightly elevated and the neu-
ronal genes has small depressions [50]. Using a cDNA
microarray, human Niemann-Pick C1 fibroblasts revealed
oxidative stress, impairment of trafficking and regulation
of calcium in response to abnormal cholesterol and GSLBMC Neuroscience 2008, 9:76 http://www.biomedcentral.com/1471-2202/9/76
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accumulation [51]. This is quite different from that
obtained in our prosaposin deficient mice. The transcrip-
tion profiles demonstrated that molecular changes
involved proinflammation, trafficking, and loss of neuron
cells. These results suggest a GSL and cellular specificity in
response to the disease. Interestingly, several lysosomal
enzymes showed up-regulation (β-glucuronidase, α-man-
nosidase and β-hexosaminidase A and B) in the present
models, suggesting altered lysosomal function compen-
sating for GSL storage.
Conclusion
The microarray analyses in this study begin to dissect the
complex interactions that underlie GSL disease progres-
sion. Regionally-specific gene expression abnormalities
preceded the histological and neuronal phenotype
changes. The proinflammatory response of microglial
cells and astrocytes likely propagated the disease and
played an important role in neurodegeneration. CEBPD is
apparently a candidate regulator participated in disease
progression in prosaposin deficiency. These results pro-
vide insight into the molecular mechanism in the progres-
sion of GSL disease and therapeutic potential for the
acquired CNS degenerative disorders that involve GSL.
Methods
Behavioral assessments
Narrow bridges
The mice were tested on square and round wood beams
during the training and test phases. Square beams (1 m in
length) with cross sectional areas of 25 mm2, 12 mm2,
and 5 mm2, and round beams (1 m in length) with diam-
eters of 28, 17, and 11 mm were used. Beams were placed
horizontally 50 cm above the floor surface. Both ends of
the beam were mounted to narrow supports. The starting
point of the beam was illuminated with a 125 W flood-
light and two Halogen lights. The end of the beam was
attached to an enclosed 20 cm2 dark box. For the training
phase, the mice traversed the 12 mm2 beam for 3 consec-
utive days, 4 trials per day. The first trial was a maximum
of 2 min and each subsequent trial was a maximum of 1
min. A successful beam cross was recorded when an ani-
mal passed the second support closest to the goal box.
Animals were considered to be trained when they crossed
the 12 mm2 beam in less than 20 sec. If a mouse failed to
traverse the beam on the first day, on the second day the
mouse was allowed to start the trials in the middle of the
beam. Once the mouse successively traversed the beam,
the start position was moved back to the original location.
The test phase began on the fourth day and each mouse in
turn received two consecutive trials (up to 60 sec/trial) on
each of the square and round beams, progressing from
widest to narrowest. Latency to traverse each beam and
the number of times the hind feet slipped off the beam
were recorded. A total of 10 PS-NA and 10 age matched
WT mice were included in the test. The tests were started
when mice were 6 wks old and repeated every two wks.
Student's t-test was used to evaluate the data.
Locomotor activity
Individual mice (5 PS-NA and 5 WT) were placed in activ-
ity chambers for 120 min under standard fluorescent
room lighting. The mutant and control mice were tested at
the same time in identical chambers, locomotor activity
was measured in a 41 × 41 × 30 cm Accuscan activity mon-
itor equipped with 16 pairs of photodetector-LED beams
along the x and y axes (Accuscan Electronics with Versa-
Max software, Columbus, OH). The apparatus was
cleaned with 70% ethanol solution between animals.
Horizontal activity was recorded in 5 min intervals. PS-NA
and WT mice were tested in an alternating order in each
test to minimize time of day effects. The test was initiated
at 6 wks of age and repeated every three wks.
Gait Analysis
Fore- and hind-paws of mice were coated with non-toxic
blue and red water-based paint, respectively, and allowed
to walk through a 60 cm runway. Footprint patterns were
recorded on white paper lining the runway. Stride length
and fore- or hind-paw base width were measured.
Histological Studies
Karnovsky's fixative was used for Electron Microscopy
(EM) analyses. For Calbindin D28K staining, paraffin-
embedded brain tissue was incubated with mouse anti-
calbindin antibody (1/500) (Sigma, C9848). For CD68
and NeuN staining, the paraformaldehyde-fixed tissue
sections were used with mouse anti-rat CD68 (Serotec,
FA-11) or anti-NeuN antibodies (1/500) (Chemicon,
MAB 377). Detection was performed using ABC
Vectastain and Alkaline phosphatase kit II-Black (Vector
Laboratory). The slides were counter stained with methyl-
green (Vector Laboratory) and visualized by light micros-
copy. For GFAP and Caspase-3 staining,
paraformaldehyde-fixed (4%) tissue sections were
blocked in 20% goat serum (GS), and incubated in mouse
anti-GFAP monoclonal antibody (Sigma, G3893) or rab-
bit anti-caspase-3 antibodies (Chemicon, AB3623) (1/50
diluted in PBS with 20% GS). FITC conjugated goat anti-
mouse or anti-rabbit antibody (ICN/CAPPEL) (1/1000 in
PBS) was applied to the sections. The sections were coun-
terstained with Antifade with DAPI (Vector Laboratory).
The signals were visualized with a fluorescent microscope
equipped with an apotome.
RNA preparation and Microarray hybridization
Cerebrum and cerebellum were collected from Prosaposin
null (PS-/-) mice at 0, 10, 20 and 25 days, prosaposin
hypomorphic (PS-NA) at 0, 4, 12 and 18 wks, V394L/
V394L glucocerebrosidase mutation and PS-NA mice (4L/BMC Neuroscience 2008, 9:76 http://www.biomedcentral.com/1471-2202/9/76
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PS-NA) at 4, 12 and 18 wks, and WT mice at 0, 10, 20 days
and 4, 12, and 18 wks. The strain background of PS-NA,
PS-/- and WT was FVB. 4L/PS-NA mice were in mixed
strains (50% FVB, 25% C57BL/6, 25% 129SvEvBrd). For
each genotype six mice at each time point were used. Total
RNA was extracted using TOTALLY RNA kit (Ambion
Inc.). RNAs for microarray analysis were generated from
six mice at each time point for each tissue, three of which
were pooled to make two separate samples for each geno-
type, brain region, and age. A total of 68 pooled RNA sam-
ples (16 for PS-/-, 16 for PS-NA, 12 for 4L/PS-NA and 24
for WT) were submitted to the CCHRF Affymetrix Micro-
array Core for hybridization to Affymetrix GeneChip
Mouse Genome 430 2.0 Array. Labeled cRNA synthesis,
GeneChip hybridization, washing and staining followed
standard Affymetrix protocols. The probe arrays were
scanned by the Affymetrix GeneChip® Scanner 3000. The
intensity for each feature of the array was captured with
GeneChip Operating Software (GCOS) v1.1.1, according
to standard Affymetrix procedures.
GeneChip quality assessment
Array data was assessed for quality using Affymetrix man-
ual procedures based on scaling factor, 10–50; percent
present, > 30%; and housekeeping gene yielding 3'/5' sig-
nal ratios, < 3. Global normalization for outliers or "bad
chips" was conducted with each sample/chip. The nor-
malized intensity values were subjected to hierarchical
clustering to determine the relative similarity of tissues
derived from different developmental stages and to iden-
tify the outlier(s) or bad chips. Genechips that passed
these screenings were used for subsequent analyses to
identify genes significantly regulated by prosaposin, time,
and region.
Microarray data
The unprocessed raw microarray data for this study is
available at Gene Expression Omnibus database (GEO) at
NCBI (accession number: GSE8307).
Microarray data normalization and analysis
The data for each mouse model and corresponding WT
controls, including those from cerebellum and cerebrum,
and from 3 or 4 time points were loaded into Partek
Genomics Suite 6.2 (Partek Inc., St. Louis, MO, USA) for
analyses and normalization using the RMA (Robust Multi-
array Average) algorithm [52]. Sample relationships were
examined using principal components analysis to reveal
any technical effects that would encumber the subsequent
analysis. To identify expression changes between geno-
types, a mixed-model ANOVA was performed and chosen
to partition subject, tissue, age, and mouse genotype. The
following linear mixed model (equation) was used to
detect differential expression on a gene-by-gene basis:
Yijkm = Gi+Tj+Ak+GTAijk+Sm+εijkm
Where yijkm is the expression of the gene for ith genotype,
jth tissue, kth age and mth subject. The symbols G, T, A,
GTA and S represent effects due to genotype (G), tissue
(T), age (A), genotype-by-tissue-by-age interaction (GTA),
and subject (S), respectively. The error for each gene for
sample ijk is designated as εijkm. Genotype, tissue and age
are fixed effects and subject is a random effect in the
mixed model. For each comparison, a linear contrast was
set up to obtain the relative fold changes between each
mutant to WT control for each tissue at all time points. Six
contrasts were added in the computation: PS-/- vs. Con-
trol, PS-NA vs. Control and 4L/PS-NA vs. Control in cere-
bellum and cerebrum, respectively. False Discovery Rate
(FDR) was performed to further protect against false pos-
itives because of multiple testing [53]. FDR was set at 0.2
and fold change was set at 1.5. Using these criteria, signif-
icantly differentially expressed genes were identified in
cerebellum and cerebrum for each model through the
time course (Table 2). Those genes were sorted into those
that were up- or down-regulated (fold change ≥ |± 1.5|)
for each time point (Table 3).
Functional classification
Significantly differentially expressed genes were subjected
to an intensive search to identify biological functions.
Functional classifications were performed using the Gene
Ontology classification obtained through the NetAffx
server [54], Gene Ontology database [55], and public
information and/or literature references. The hypergeo-
metric distribution was performed using R 2.6.0 [56] to
detect the significant functional categories which were
regarded significant with p-value < 0.05. Based on 1) high
scoring homologies of the corresponding encoded pro-
teins to known proteins using biochemical function and
molecular process concepts represented in Gene Ontology
and 2) the statistical significance of differentially regu-
lated functional groups across two tissues in the three ani-
mal models; those differentially expressed genes were
grouped into the following categories (Table 4): inflam-
mation/macrophages, myelination, synaptic vesicle, cell
death, lipid metabolism, extracellular matrix (ECM)/cell
adhesion, cytoskeleton organization, endosome/lyso-
some, signal transduction, transcription, transport, cell
growth/metabolism, binding (nucleotide binding, pro-
tein binding, lipid binding, etc.), catalytic activity and
others. Some of the genes were grouped into more than
one functional category. A complete gene list with tempo-
ral expression changes by functional grouping is in Addi-
tional file 1.
Partitioned clustering of gene expression profiles
K means clustering was applied for partitioned clustering
to subdivide functionally classified genes into groupsBMC Neuroscience 2008, 9:76 http://www.biomedcentral.com/1471-2202/9/76
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based on similarities in expression profiles for each tissue
throughout development. Similarities between expression
profiles from different genes were determined using the
coefficient of shape applied to log2 transformed mean
expression values for each genotype at each time point.
Gene expression profiles for the clusters were visualized
using GeneSpring GX 7.3 (Agilent Technologies, Inc.,
Santa Clara, CA).
Network construction
The significantly differentially expressed genes in the cer-
ebellum and cerebrum of PS-/-, PS-NA and 4L/PS-NA
were loaded into PathwayArchitect 2.0.1 (Stratagene, La
Jolla, CA) and built into a CEBPD-associated interaction
network. Some interactions were referenced from Ingenu-
ity Pathways Analysis (Ingenuity Systems, Inc.). Each
functional group was highlighted in a different color.
Quantitative RT-PCR
Total RNA was extracted from tissues of three mice using
TOTALLY RNA (Ambion Inc.). Those RNA samples used
for Quantitative RT-PCR (qRT-PCR) were from the pooled
RNAs subjected for Microarray analysis. Reverse transcrip-
tion of 10 μg of total RNA for each tissue was carried out
using High Capacity cDNA Archive Kit (Applied Biosys-
tems) containing Random Hexamer primers. qRT-PCR
was performed as previously described using β-actin as an
internal control on ABI Prism 7000 Sequence Detection
System [57]. Data were presented as means ± S.E. The
primer sequences were as in Additional file 3.
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